CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 21 enrolled
Drug / intervention
ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04049474
NCT04049474Early Ph 1Completed
CompareCT.gov

Bronchoscopic Cryo-Immunotherapy of Lung Cancer

NYU Langone Health·interventional·Posted Aug 8, 2019·Updated Apr 24, 2025

In Brief

A Early Phase 1 clinical trial evaluating ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany) for Advanced Non-small Cell Lung Cancer. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This is a safety and feasibility study of bronchoscopic cryo-immunotherapy (BCI) of peripheral lung tumors in advanced non-small cell lung cancer for the intention of inducing anti-tumor immune responses. The sample size for this study will be 15 patients. Pre- and post- BCI peripheral blood samples will be analyzed to assess for anti-tumor immune responses. Post-BCI peripheral blood will be collected 7 and 14 days after the procedure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Non-small Cell Lung Cancer
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedAug 8, 2019
Enrollment StartFeb 15, 2020
Primary CompletionApr 9, 2024
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 6.9 years ago

Interventions

ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)device

See BCI description.